JAC Advance Access originally published online on September 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 538-542
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
Ertapenem, the first of a new group of carbapenems
1 J.W. Goethe-Universitaet, Frankfurt, Germany; 2 Merck Research Laboratories, West Point, PA 19486, USA
Keywords: ertapenem, imipenem, meropenem, clinical trials, carbapenems
| The first 150 words of the full text of this article appear below. |
ß-Lactam antimicrobials have been widely prescribed to treat serious infections for nearly 60 years owing to their excellent efficacy, safety and tolerability profiles. Among the many different structurally distinct classes of ß-lactams, the carbapenem class, while sharing these general ß-lactam features, is regarded as the class that is most potent and that has the widest spectrum of antimicrobial activity. At the time that the carbapenems were last reviewed in this journal,1 imipenem and meropenem were the only carbapenems that were available in the majority of the world. Since then ertapenem (formerly MK-0826), a new long-acting, parenteral carbapenem (Figure 1), has received regulatory approval in the United States (November 2001) and the European Union (April 2002).
| |||||||||||
The introduction of ertapenem should make us reconsider how we think of the carbapenems. Ertapenem is sufficiently different in some key attributes from imipenem and
 |
Imipenem and meropenem |
|---|
Pharmacology
Microbiology
Clinical use
Adverse reactions
|
Ertapenem |
|---|
Pharmacology
Microbiology
Clinical use
Adverse reactions
|
What is the role for ertapenem? |
|---|
|
A classification scheme for carbapenems |
|---|
|
Conclusions |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. J. C. Goldstein, D. M. Citron, V. Peraino, T. Elgourt, A. R. Meibohm, and S. Lu Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5122 - 5126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Leavitt, I. Chmelnitsky, R. Colodner, I. Ofek, Y. Carmeli, and S. Navon-Venezia Ertapenem Resistance among Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae Isolates J. Clin. Microbiol., April 1, 2009; 47(4): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Mallalieu, S. Lennon, M. Liu, C. Kirkpatrick, R. Robson, E. Luedin, and B. E. Davies Effect of Impaired Renal Function on the Pharmacokinetics of Tomopenem (RO4908463/CS-023), a Novel Carbapenem Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2360 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Boselli, D. Breilh, S. Djabarouti, J. C. Bel, M. C. Saux, and B. Allaouchiche Diffusion of ertapenem into bone and synovial tissues J. Antimicrob. Chemother., October 1, 2007; 60(4): 893 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. B. Amyes, F. M. Walsh, and J. S. Bradley Best in class: a good principle for antibiotic usage to limit resistance development? J. Antimicrob. Chemother., May 1, 2007; 59(5): 825 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Burkhardt, V. Kumar, D. Katterwe, J. Majcher-Peszynska, B. Drewelow, H. Derendorf, and T. Welte Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration J. Antimicrob. Chemother., February 1, 2007; 59(2): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M.F. Itani, S. E. Wilson, S. S. Awad, E. H. Jensen, T. S. Finn, and M. A. Abramson Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery N. Engl. J. Med., December 21, 2006; 355(25): 2640 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Rodloff, E. J. C. Goldstein, and A. Torres Two decades of imipenem therapy J. Antimicrob. Chemother., November 1, 2006; 58(5): 916 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. N. Nafziger, G. L. Drusano, L. Ma, and J. S. Bertino Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1222 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. DiNubile, J. W. Chow, V. Satishchandran, A. Polis, M. R. Motyl, M. A. Abramson, and H. Teppler Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3217 - 3221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Burkhardt, J. Majcher-Peszynska, K. Borner, R. Mundkowski, B. Drewelow, H. Derendorf, and T. Welte Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery J. Clin. Pharmacol., June 1, 2005; 45(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Seto, J. C Song, and S. S Guest Ertapenem-Associated Seizures in a Peritoneal Dialysis Patient Ann. Pharmacother., February 1, 2005; 39(2): 352 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. R. Pletz, M. Rau, J. Bulitta, A. De Roux, O. Burkhardt, G. Kruse, M. Kurowski, C. E. Nord, and H. Lode Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3765 - 3772. [Abstract] [Full Text] [PDF]
|
|